Scarica l'app Stockscreener
0.9495
6.67%
0.0594
Precedente Chiudi:
$0.8901
Aprire:
$0.9546
Volume 24 ore:
21,944
Relative Volume:
0.02
Capitalizzazione di mercato:
$67.94M
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
-
1 W Prestazione:
+6.69%
1M Prestazione:
+2.65%
6M Prestazione:
-34.97%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$0.89
$0.9546
Intervallo di 1 settimana:
$0.825
$0.9546
Portata 52W:
$0.5506
$2.87
Citius Oncology Inc Stock (CTOR) Company Profile
Nome
Citius Oncology Inc
Settore
Telefono
(908) 967-6677
Indirizzo
11 COMMERCE DRIVE, CRANFORD
Confronta CTOR con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CTOR
Citius Oncology Inc
|
0.9495 | 63.68M | 0 | 0 | 0 | 0.00 |
|
HLN
Haleon Plc Adr
|
11.18 | 50.54B | 14.35B | 1.85B | 0 | 0.4023 |
|
ZTS
Zoetis Inc
|
170.91 | 74.02B | 9.29B | 2.52B | 2.28B | 5.57 |
|
RDHL
Redhill Biopharma Ltd Adr
|
1.8368 | 4.22M | 35.75M | 11.57M | -26.25M | -3.8069 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.99 | 45.82B | 30.08B | 710.16M | 4.45B | 0.2182 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
17.34 | 20.31B | 16.54B | -1.64B | 749.00M | -1.45 |
Citius Oncology Inc Stock (CTOR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-11-27 | Iniziato | Maxim Group | Buy |
Citius Oncology Inc Borsa (CTOR) Ultime notizie
This Deckers Outdoor Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday - Benzinga
Maxim Downgrades Citius Oncology to Hold From Buy - marketscreener.com
Citius Oncology (CTXR) Seeks Additional Capital for LYMPHIR Laun - GuruFocus
Citius Oncology (CTXR) Seeks Additional Capital for LYMPHIR Launch | CTXR Stock News - GuruFocus
Citius Oncology, Inc. Reports Fiscal Second Quarter 2025 Financial Results And Provides Business Update - marketscreener.com
Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2025 Financial Results and Provides Business Update - PR Newswire
Citius Oncology, Inc. (NASDAQ:CTOR) Is Expected To Breakeven In The Near Future - Yahoo Finance
Citius Pharmaceuticals to Present at the Jefferies Global Healthcare Conference | CTXR Stock News - GuruFocus
Citius Pharmaceuticals to Present at the Jefferies Global Healthcare Conference - PR Newswire
US Stocks Dip As Investors Eye Trump's Tariff Announcements - Finimize
Citius Oncology IncReceives Nasdaq Notice For Bid Price Non-ComplianceSEC Filing - marketscreener.com
Citius Oncology (NASDAQ:CTOR) Trading 6.3% Higher – Still a Buy? - Defense World
Citius Pharmaceuticals Announces $2 Million Registered Direct Offering of Common Stock - Longview News-Journal
Citius Oncology Inc (NASDAQ: CTOR) Is On The Fall - stocksregister.com
Citius Pharma secures $2 million in stock offering By Investing.com - Investing.com South Africa
Citius Pharma secures $2 million in stock offering - Investing.com India
Citius Oncology (NASDAQ:CTOR) Shares Up 39.8% – Still a Buy? - Defense World
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
3 Penny Stocks to Watch Now, 4/1/25 - TipRanks
Citius Secures Strategic $2M Funding to Accelerate LYMPHIR LaunchKey Details Revealed - Stock Titan
Why Citius Oncology Inc. Stock Spiked Over 7%? - timothysykes.com
Why Xos Shares Are Trading Higher By Around 9%; Here Are 20 Stocks Moving Premarket - Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session - Benzinga
IFP Advisors Inc Has $26,000 Stock Position in Citius Oncology, Inc. (NASDAQ:CTOR) - Defense World
Citius Oncology, Inc. Reports Fiscal First Quarter 2025 Financia - GuruFocus.com
Citius Pharma's LYMPHIR gains permanent J-code for billing - MSN
Citius Oncology (NASDAQ:CTOR) Issues Earnings Results - MarketBeat
Citius Pharmaceuticals, Inc. Reports Fiscal First Quarter 2025 Financial Results and Provides Business Update - The Malaysian Reserve
Citius Oncology, Inc. Reports Fiscal First Quarter 2025 Financial Results and Provides Business Update - 69News WFMZ-TV
Citius Oncology Inc. (CTOR) reports earnings - Quartz
CITIUS ONCOLOGY, INC. SEC 10-Q Report - TradingView
Citius Oncology Preps LYMPHIR Cancer Drug Launch While Strategic Review Unfolds - StockTitan
Citius Pharmaceuticals Secures Critical J-Code for LYMPHIR as Cash Reserves Hit $1.1M - Stock Titan
Citius Pharmaceuticals (NASDAQ:CTXR) Announces Issuance of Permanent J-Code for LYMPHIR by CMSOn February 6, 2025, Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) disclosed in an 8-K filing that the company and its oncology subsidiary, Citius Oncol - Defense World
Citius Pharma’s LYMPHIR gains permanent J-code for billing By Investing.com - Investing.com Nigeria
Citius Pharma's LYMPHIR gains permanent J-code for billing By Investing.com - Investing.com Australia
Medicare Breakthrough: Citius's Cancer Drug LYMPHIR Gets Crucial Insurance CodeMajor Win for CTCL Patients - StockTitan
Citius Oncology (NASDAQ:CTOR) Shares Down 2%Here's What Happened - MarketBeat
Amendment: SEC Form 10-K/A filed by Citius Pharmaceuticals Inc. - Quantisnow
Citius Oncology, Inc. Reports Fiscal Full Year 2024 Financial Results and Provides Business Update - 69News WFMZ-TV
Citius Pharmaceuticals (NASDAQ: CTXR) Announces Progress in LYMPHIR Commercial Launch Preparation - Defense World
Citius Pharmaceuticals Announces $3 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules - BioSpace
Citius Pharmaceuticals Secures $3M Through Strategic Share Offering with 5-Year Warrants - StockTitan
Citius Pharmaceuticals and Citius Oncology Highlight LYMPHIR Commercial Launch Planned for the First Half of 2025 - PR Newswire
Citius Oncology to explore strategic alternatives - Yahoo Finance
Citius Oncology Inc Azioni (CTOR) Dati Finanziari
Non sono disponibili dati finanziari per Citius Oncology Inc (CTOR). Controlla altri titoli per ulteriori informazioni.
Reddito
Reddito netto
Flusso di cassa
EPS
3.28%
2.99%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):